New Lilly GLP‑1 pill out
Eli Lilly’s oral GLP‑1 weight‑loss pill became available for purchase in the United States starting Thursday, April 9, adding a non‑injectable option to the category and widening patient access (upi.com). That launch could change how people choose therapies — some will prefer pills over injections for convenience, which may shift prescribing and retail patterns quickly (upi.com).
A weight-loss drug that used to mean a weekly shot now has a daily pill version on U.S. shelves, and Eli Lilly says adults could start buying Foundayo on Thursday, April 9, 2026, just eight days after federal approval. (upi.com) Foundayo is Lilly’s brand name for orforglipron, and the Food and Drug Administration approved it on April 1, 2026, for adults with obesity or adults with overweight plus at least one weight-related medical problem. (fda.gov) These drugs copy a gut hormone called glucagon-like peptide-1, which tells the brain you are full and slows how fast food leaves the stomach, so people tend to eat less. (lilly.com) Until now, the biggest names in this market mostly trained patients to think in syringes, with Novo Nordisk’s Wegovy and Lilly’s Zepbound built around injections instead of tablets. (statnews.com) Lilly’s pitch is convenience: Foundayo is a once-daily pill that can be taken at any time of day and does not require food or water rules, which removes the timing hassles attached to some older oral hormone drugs. (lilly.com) The company is also trying to make the first month feel cheap enough to try, with prices starting at $25 a month for people with commercial insurance coverage and $149 a month for self-pay patients, while shipments go through LillyDirect, telehealth partners, and retail pharmacies nationwide. (morningstar.com) The clinical hook is weight loss without needles: Lilly’s phase 3 obesity study reported placebo-adjusted weight reductions of about 9 to 11 percentage points at 72 weeks, with the best-adhering patients on the highest dose averaging 27.3 pounds, or 12.4%, of body weight lost. (ajmc.com) The safety profile still looks like the rest of the glucagon-like peptide-1 class, with nausea, vomiting, diarrhea, constipation, and stomach pain listed among common side effects in Lilly’s prescribing information. (lilly.com) That means the real shift is not that the biology changed in April 2026. The shift is that a category built on weekly injections now has a pill that doctors can prescribe through the same obesity-treatment channel, which could pull in patients who refused shots and push more competition into clinics, telehealth apps, and pharmacies at the same time. (lilly.com)
